ALCHEM LABORATORIES CORPORATION

Alchem Laboratories Corporation specializes in the synthesis and manufacturing of pharmaceutical compounds for preclinical and clinical development, with deep expertise in non-GMP small molecule chemistry, bulk active pharmaceutical ingredient production, and drug formulation. The contractor delivers end-to-end chemistry, manufacturing, and control (CMC) services, supporting drug discovery through early-stage development by producing custom compounds, scaling synthetic routes, and supplying material for in vivo and in vitro studies. Their technical capabilities encompass organic synthesis, analytical method development, and process optimization for complex drug candidates, with demonstrated experience supporting COVID-19 therapeutic trials and novel oncology agents. The firm’s niche lies in agile, incrementally funded production of low-volume, high-complexity intermediates and final drug substances under controlled research environments, bridging the gap between discovery and clinical readiness. The company maintains a consistent and exclusive relationship with the Department of Health and Human Services, delivering specialized pharmaceutical development services across multiple divisions, including NIH and FDA-affiliated programs. Their work supports both internal research initiatives and public health emergency responses, indicating a trusted, long-term partnership rooted in technical reliability and regulatory alignment. Alchem Laboratories operates primarily within NAICS 325412, focusing on pharmaceutical preparation manufacturing for government-funded research, with supplementary work in life sciences R&D and biotechnology development. This positions them as a niche supplier to the federal biopharma pipeline, serving agencies requiring rapid, flexible, and scientifically rigorous chemical manufacturing support outside commercial GMP constraints. As a 2L entity based in Alachua, Florida, the company is structured for specialized contract execution with no federal certifications on record. Their geographic location supports access to academic and research ecosystems, reinforcing their role as a technical contractor embedded within the U.S. government’s drug development infrastructure.